Genomics Case 1 Question 2B by https://padlet.com/haspelr/y2qiwashr5ebljyg 2. The patient is found to have an EGFR exon 19 deletion and is started on treatment with erlotinib. Initial scans indicate treatment response. After 16 months, however, the patient develops new symptoms and a CT scan shows progression of the disease with a new liver lesion. Molecular testing shows a new EGFR variant T790M, which confers resistance to the initially prescribed tyrosine kinase inhibitor. The patient is started on osimertinib and has stable disease until a year later, when a CT scan shows significant enlargement of the initial liver lesion and new metastatic liver foci. en-us 2021-09-16 14:56:13 UTC 2025-11-25 15:53:40 UTC hello@padlet.com Liquid Biopsy haspelr https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1746236241 A liquid biopsy is sent and you receive the report at http://bit.ly/liquidbiopsyreport.  Using CIViC (https://civicdb.org/), and OncoKB (https://oncokb.org/), what is the clinical significance of the EGFR C797S and PIK3CA E545K variants, based upon what evidence?

(Hint: Can enter just the amino acid change to search (e.g.,” c797s”); for CIViC, after selecting the variant, need to scroll down to see the specific information and then click on studies for lung adenocarcinoma under “Evidence;” for OncoKb, after selecting the variant, select “non-small cell lung carcinoma” as the “cancer type” and hover over the “level” and the number of citations)
_____________________________________________
To create a new post, double-click on a blank space or click the plus sign in the lower right-hand corner. You can ignore the  Subject line if you prefer. In the body (under the icons), type your response.  Click "Publish" when you are finished. You can resize your posts by dragging on the edges

RETURN to Main Padlet here.
]]> 2021-09-16 14:56:13 UTC https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1746236241 https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1767707133 Showing resistant mutations 
No need to continue drug ]]> 2021-09-25 19:27:56 UTC https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1767707133 https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1767708698 Egfr alt is a known resistance alteration in nsclc; pik3ca alteration is associated with response to Piqray in breast but response in lung is not known]]> 2021-09-25 19:29:50 UTC https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1767708698 https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1767711152 EGFRC797S resistance mut to osimertinib; PICK3CA E545K responds to alpelsib in breast

This information is also listed in the professional services of the Foundation Medicine report]]> 2021-09-25 19:32:54 UTC https://padlet.com/haspelr/y2qiwashr5ebljyg/wish/1767711152